+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

United States Generic Drugs Market By Segment (Generic, Branded), Therapeutic Application, Company Analysis & Forecast

  • ID: 5308279
  • Report
  • March 2021
  • Region: United States
  • 110 pages
  • Renub Research
1 of 4

FEATURED COMPANIES

  • Dr Reddy's
  • Endo Pharmaceuticals
  • Lupin Limited
  • Mylan N.V
  • Sandoz Inc.
  • Sun pharma
  • MORE
Generics are an off-patented drug that is pharmaceutical equivalents to branded medicines in term of administrative dosage, quality, effect, intended use and side effects. In the United States, generic drug production has increased because it is cheaper than any branded medicine. From the last 3 decades, U.S generic drug market has transformed from less than 20% of generic drug prescription to 80% of dispensing generic medicine prescriptions. As per the report, United States Generic Drugs Market will be US$ 239.5 Billion by 2026.

Generic medicines help maintain the country's healthcare system, from curing patients to saving money. Currently, the price of off-label drugs is 70% to 80% lower than branded medicines. In the United States, the decline in medicine price works as the biggest catalyst for the generic drug market growth. These generic medicines prices sometimes declined to 85% less than patented drugs; this happens when various generic drug companies target a single patented drug. the research findings suggest that the United States Off-Label Drugs Market will grow with a CAGR of 5.69% in future from 2020 to 2026.

The United States government awareness for the use of generic drugs reduces overall health expenditure in the country. The FDA's Office of Generic Drugs (OGD) within the Center for Drug Evaluation in Research ensures access to safe, high quality and affordable drugs to Americans. The U.S government made a law regarding the generic drug, allowing a new player to enter the market. Besides factors like the rising number of patients for diabetes, Alzheimer, cardiac diseases, an increasing number of drug patent expirations and government initiatives expected to drive the generic drugs industry. As per this research study, the United States Off-patent Drugs Market was US$ 171.8 Billion in the year 2020.

Generic Drug Companies Deals

On July 6, 2020, Endo announced that it had received FDA approval of Qwo® (collagenase clostridium histolyticum-aaes). Another company, named Lupin Limited manufactures generic drug Abacavir& Lamivudine, whose combination is being used together with other medications to treat human immunodeficiency virus (HIV) infection. The publisher has covered companies' initiatives that sell various generic drugs in the United States. Companies covered in the report are Teva Pharmaceutical Industries Ltd, Mylan N.V, Sandoz Inc, Endo Pharmaceuticals, Lupin Limited, Dr Reddy's and Sun pharma.

This report title “United States Generic Drugs Market'' By Segment (Generic, Branded), Therapeutic Application (CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective, Oncology and Others), Pharmaceutical (Branded Pharmaceutical, Generics Pharmaceutical), Company (Teva Pharmaceutical Industries Ltd, Mylan N.V, Sandoz Inc, Endo Pharmaceuticals, Lupin Limited, Dr Reddy's and Sun pharma)” provides an all-encompassing analysis on the US Generic Drug Industry.

Segment: Market breakup from 2 viewpoints
  • Generic
  • Branded
Therapeutic Application: Market breakup from 8 viewpoints

1. CNS
2. Cardiovascular
3. Dermatology
4. Genitourinary/Hormonal
5. Respiratory
6. Anti-infective
7. Oncology
8. Others

Pharmaceutical: Market breakup from 2 viewpoints
  • Branded Pharmaceutical
  • Generics Pharmaceutical
All the Company Analysis have covered 3 Viewpoints
  • Overview
  • Recent Developments
  • Revenue Analysis
Company Analysis

1. Teva Pharmaceutical Industries Ltd
2. Mylan N.V
3. Sandoz Inc.
4. Endo Pharmaceuticals
5. Lupin Limited
6. Dr Reddy's
7. Sun pharma
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Dr Reddy's
  • Endo Pharmaceuticals
  • Lupin Limited
  • Mylan N.V
  • Sandoz Inc.
  • Sun pharma
  • MORE
1. Introduction

2. Executive Summary

3. Market Dynamics
3.1 Growth Driver
3.2 Challenges

4. United States Drugs Market
4.1 Branded Drugs Market
4.2 Generics Drugs Market

5. United States Generic Drugs Saving

6. Market Share - United States Drugs Analysis
6.1 Branded vs. Generics Drugs
6.2 Branded Generic vs. Unbranded Generic Drug
6.3 Volume Penetration - Generic vs. Branded Drugs
6.4 Therapeutic Application

7. United States Generic Drugs Market
7.1 Branded Generic Drugs Market
7.2 Unbranded Generic Drugs Market

8. Therapeutic Application - United States Generic Drugs Market
8.1 Central Nervous System (CNS)
8.2 Cardiovascular
8.3 Dermatology
8.4 Genitourinary / Hormonal Drugs
8.5 Respiratory
8.6 Anti-infective
8.7 Oncology
8.8 Others

9. Company Analysis
9.1 Teva Pharmaceutical Industries Ltd
9.1.1 Overview
9.1.2 Product Launch
9.1.3 Financial Insight
9.2 Mylan N.V.
9.2.1 Overview
9.2.2 Product Launch
9.2.3 Financial Insight
9.3 Sandoz Inc.
9.3.1 Overview
9.3.2 Product Launch
9.3.3 Financial Insight
9.4 Endo Pharmaceuticals
9.4.1 Overview
9.4.2 Product Launch
9.4.3 Financial Insight
9.5 Lupin Limited
9.5.1 Overview
9.5.2 Product Launch
9.5.3 Financial Insight
9.6 Dr Reddy's
9.6.1 Overview
9.6.2 Product Launch
9.6.3 Financial Insight
9.7 Sun Pharmaceutical Industries Ltd.
9.7.1 Overview
9.7.2 Product Launch
9.7.3 Financial Insight

List of Figures:
Figure 3-1: United States - Rising Geriatric Population (Million), 2000, 2016 & 2060
Figure 4-1: US - Pharma Market (Billion US$), 2015 - 2020
Figure 4-2: US - Forecast for Pharma Market (Billion US$), 2021 - 2026
Figure 4-3: US- Branded Pharma Market (Billion US$), 2015 - 2020
Figure 4-4: US - Forecast for Branded Pharma Market (Billion US$), 2021 - 2026
Figure 4-5: US- Generics Pharma Market (Billion US$), 2015 - 2020
Figure 4-6: US - Forecast for Generics Pharma Market (Billion US$), 2021 - 2026
Figure 5-1: Top 10 Generic Drugs Ranked by Savings in US - 2016
Figure 5-2: Ten Major US State Generic Saving in - 2016
Figure 5-3: Savings from Generics in (Billions US$), - 2016
Figure 5-4: US - Generic Drugs Saving (Billion US$), 2015 - 2020
Figure 5-5: US - Forecast for GenericDrugs Saving (Billion US$), 2021 - 2026
Figure 6-1: Branded VS Generic Drug Market Share (%), 2015 - 2020
Figure 6-2: Forecast for - Branded VS Generic Drug Market Share (%), 2021 - 2026
Figure 6-3: Branded Generic vs. Unbranded Market Share (%), 2015 - 2020
Figure 6-4: Forecast for - Branded Generic vs. Unbranded Market Share (%), 2021 - 2026
Figure 6-5: Generic V.S. Branded Drug Volume Penetration (%), 2015 - 2020
Figure 6-6: Forecast for - Generic V.S. Branded Drug Volume Penetration (%), 2021 - 2026
Figure 7-1: Branded - Generic Drug Market (Billion US$), 2015 - 2020
Figure 7-2: Branded - Forecast for Generic Drug Market (Billion US$), 2021 - 2026
Figure 7-3: Unbranded - Generic Drug Market (Billion US$), 2015 - 2020
Figure 7-4: Unbranded - Forecast for Generic Drug Market (Billion US$), 2021 - 2026
Figure 8-1: Central Nervous System Market (Billion US$), 2015 - 2020
Figure 8-2: Forecast for - Central Nervous System Market (Billion US$), 2021 - 2026
Figure 8-3: U.S Incidence of cardiovascular disease by age and sex - 2013
Figure 8-4: Cardiovascular Market (Billion US$), 2015 - 2020
Figure 8-5: Forecast for Cardiovascular Market (Billion US$), 2021 - 2026
Figure 8-6: Skin Diseases Prevalence in US - 2013
Figure 8-7: Dermatology Market (Million US$), 2015 - 2020
Figure 8-8: Forecast for - Dermatology Market (Million US$), 2021 - 2026
Figure 8-9: Genitourinary/Hormonal Drugs Market (Billion US$), 2015 - 2020
Figure 8-10: Forecast for - Genitourinary/Hormonal Drugs Market (Billion US$), 2021 - 2026
Figure 8-11: Respiratory Market (Billion US$), 2015 - 2020
Figure 8-12: Forecast for - Respiratory Market (Billion US$), 2021 - 2026
Figure 8-13: Anti - infective Market (Billion US$), 2015 - 2020
Figure 8-14: Forecast for Anti - infective Market (Billion US$), 2021 - 2026
Figure 8-15: Oncology Market (Billion US$), 2015 - 2020
Figure 8-16: Forecast for - Oncology Market (Billion US$), 2021 - 2026
Figure 8-17: Others Market (Billion US$), 2015 - 2020
Figure 8-18: Forecast for - Others Market (Billion US$), 2021 - 2026
Figure 9-1: Teva - US Generic Drugs Market (Million US$), 2015 - 2020
Figure 9-2: Teva - Forecast for US Generic Drugs Market (Million US$), 2020 - 2026
Figure 10-1: Mylan NV - US Generic Drugs Market (Million US$), 2015 - 2020
Figure 10-2: Mylan NV - Forecast for Mylan NV US Generic Drugs Market (Million US$), 2021 - 2026
Figure 11-1: Sandoz - US Generic Drugs Market (Million US$), 2015 - 2020
Figure 11-2: Sandoz - Forecast for Sandoz US Generic Drugs Market (Million US$), 2021 - 2026
Figure 12-1: Endo Pharmaceuticals - US Generic Drugs Market (Million US$), 2015 - 2020
Figure 12-2: Endo Pharmaceuticals - Forecast for US Generic Drugs Market (Million US$), 2021 - 2026
Figure 13-1: Lupin Limited - US Generic Drugs Market (Million US$), 2015 - 2020
Figure 13-2: Lupin Limited - Forecast for US Generic Drugs Market (Million US$), 2021 - 2026
Figure 14-1: Dr Reddy's - North America (US & Canada) Generic Drugs Market (Million US$), 2015 - 2020
Figure 14-2: Dr Reddy's - Forecast for North America (US & Canada) Generic Drugs Market (Million US$), 2021 - 2026
Figure 15-1: Sun Pharma - US Generic Drugs Market (Million US$), 2015 - 2020
Figure 15-2: Sun Pharma - Forecast for US Generic Drugs Market (Million US$), 2021 - 2026
Figure 16-1: Others - US Generic Drugs Market (Million US$), 2015 - 2020
Figure 16-2: Others - Forecast for US Generic Drugs Market (Million US$), 2021 - 2026

List of Tables:
Table 6-1: US Generic Drugs - Therapeutic Application Market Share (%), 2015 - 2020
Table 6-2: US Generic Drugs - Forecast for Therapeutic Application Market Share (%), 2021 - 2026
Table 8-1: The Full Burden of 24 Skin Disease categories
Note: Product cover images may vary from those shown
3 of 4
  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V
  • Sandoz Inc.
  • Endo Pharmaceuticals
  • Lupin Limited
  • Dr Reddy's
  • Sun pharma
Note: Product cover images may vary from those shown
4 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll